IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?

Kow, Chia Siang; Zaihan, Abdullah Faiz; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad

Kow, Chia Siang; Zaihan, Abdullah Faiz; Ramachandram, Dinesh Sangarran; Hasan, Syed Shahzad.

Kow CS; School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia; School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor, Malaysia. Electronic address: chiasiang_93@hotmail.com.
Zaihan AF; Department of Pharmacy, Shah Alam Hospital, Persiaran Kayangan, Seksyen 7, Shah Alam, Selangor, Malaysia.
Ramachandram DS; School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor, Malaysia.
Hasan SS; School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom; School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.

Cytokine ; 149: 155730, 2022 01.

Article in English | MEDLINE | ID: covidwho-1506249

Subject(s)

Adrenal Cortex Hormones/therapeutic use; Anti-Inflammatory Agents/therapeutic use; COVID-19 Drug Treatment; Interleukin-6/antagonists & inhibitors; COVID-19/diet therapy; Humans; Prospective Studies

Keywords

COVID-19; Corticosteroid; IL-6 antagonist; Sarilumab; Tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-6 / Adrenal Cortex Hormones / COVID-19 Drug Treatment / Anti-Inflammatory Agents Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: Cytokine Journal subject: Allergy and Immunology Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google